Demant identifies cochlear implant fault, plans market return in late 2022
Hearing aid giant Demant has got to the bottom of the fault which has caused problems with one of its cochlear implant products, and expects to resume sales in the third quarter of 2022.
by mikkel aabenhus hemmingsen, translated by catherine brett
According to Demant, the problems with its Neuro Zti cochlear implants are close to being resolved.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Questions about Demant's future remain as 2022 nears
For subscribers
GN Hearing loses Veterans Affairs market shares in November
For subscribers
Swiss media reports of defective Sonova cochlear implants
For subscribers
